# V45 Queue: Continuous Self-Directed Research Block

Block start UTC: 2026-06-12T16:06:13Z
Target UTC (+360 min): 2026-06-12T22:06:13Z

## Stop Conditions

Valid stops only:

1. cumulative measured runtime >= 360 minutes and clean resumable point;
2. external termination;
3. documented all-fronts block after every internally executable alternative is exhausted.

Backlog exhaustion is not a stop. When executable todo items drop below five,
generate more internally executable tasks before continuing.

## Iterations

| Iteration | Start UTC | End UTC | Status | Notes |
|---|---:|---:|---|---|
| 1 | 2026-06-12T16:06:13Z |  | in-progress | Initialized V45. OpenGWAS POST check passed; JWT expires 2026-06-19 12:28 UTC. SAP AI Core Claude/Gemini/RPT smoke-passed. |

## Live Backlog

| Priority | Front | Item | Status | Notes |
|---:|---|---|---|---|
| 1 | Cohort dependence | Write concrete Karolinska DMF label-access package and exact request steps | done | Wrote `docs/validation/KAROLINSKA_DMF_LABEL_REQUEST_V45.md`; verified GEO/PubMed metadata into `analysis/v45_karolinska_access/`; blocker is labels plus GSM-to-patient/timepoint map. |
| 2 | Cohort dependence | Deep paper/supplement scout specifically for GSE228330 anti-CD20/ocrelizumab outcomes | in-progress | Determine whether clinical outcomes are recoverable outside GEO; usable only if labels map to samples. |
| 3 | Robustness | Extend batch guard simulations to multi-confounder technical structures | todo | Test batch + immune-tone + normalization interactions; synthetic method behavior only. |
| 4 | Robustness | Stress-test V44 postpartum APC-arm harness under missing timepoints, steroid metadata, and batch imbalance | todo | Synthetic-only; no rule change. |
| 5 | Robustness | Stress-test V44 T/B compartment harness under composition shifts and compartment-label noise | todo | Synthetic-only; no rule change. |
| 6 | Power/design | Produce medical-team cohort specification from V43/V44 simulations | todo | Exact n, timepoints, metadata, batch constraints, and label requirements for conclusive validation. |
| 7 | Data-free validation | Run alternative convergence nulls using evidence-row weighting and source-family collapse | todo | Sensitivity for V44 recurrence without changing biological claim. |
| 8 | Data-free validation | Leave-one-artifact-family-out APC convergence check | todo | Tests whether report-derived artifacts inflate recurrence. |
| 9 | Infrastructure | Package validation harness command templates and expected input schemas into a reusable validation README | todo | Durable CS output. |
| 10 | Infrastructure/RPT | Exercise RPT on V44 structured readiness tables as proposal-only and verify no evidence claim changes | todo | RPT output must be grounded or labeled proposal-only. |
| 11 | External account | Expand skeptical peer-review draft into methods/limitations checklist with rebuttal table | todo | Surfaces gaps; synthesis only. |
| 12 | Pre-registration breadth | Draft data-ingestion preregistration skeleton for open pharmacodynamic-only cohorts such as GSE228330 | todo | Analysis-only context, not response validation. |

## Generated Follow-Ups

Generated tasks must be added here before backlog drops below five executable
todo items.

## Per-Iteration Notes

- Iteration 1 started at 2026-06-12T16:06:13Z.
- Tooling health: OpenGWAS POST check passed; SAP AI Core Claude/Gemini/RPT
  smoke-passed. RPT remains proposal-only.
- First selected task: Karolinska DMF label-access package.
- Karolinska access package completed at 2026-06-12T16:09:44Z plus metadata
  verification run. Public GEO records verify `GSE130478` expression has `28`
  CD4+ T-cell samples from `14` MS patients at baseline/6 months, `GSE130491`
  methylation has `82` samples, and the public blocker is patient-level
  beneficial-response labels plus GSM-to-patient/timepoint mapping.
- New generated follow-up: if Karolinska labels arrive, write a secondary
  Karolinska-specific preregistration before any module scoring because the
  platform and timing differ from Gafson/V42.
- Next selected task: GSE228330 anti-CD20/ocrelizumab outcome scout.
